Oxaliplatin Effective as Cisplatin for Treatment-Naive Gastric Cancer

Share this content:

the Cancer Therapy Advisor take:

According to a new study published in the journal Annals of Oncology, S-1, a novel oral dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, plus oxaliplatin (SOX) is as effective as S-1 plus cisplatin (CS) for the first-line treatment of patients with advanced gastric cancer and is well tolerated.

For the open-label, multicenter phase 3 study, 685 patients with newly diagnosed gastric cancer were randomly assigned to receive S-1 120mg/day for 2 weeks plus oxaliplatin 100mg/m2 on day 1 every 3 weeks or S-1 120mg/day for 3 weeks plus cisplatin 60mg/m2 on day 8 every 5 weeks.

Results showed that in the per-protocol population, the median progression-free survival was 5.5 and 5.4 months for SOX and CS, respectively (HR = 1.004; 95% CI: 0.840 - 1.199). The median overall survival for SOX was 14.1 months compared with 13.1 months for CS (HR = 0.958; 95% CI: 0.803 - 1.142).

In the intention-to-treat population, the hazard ratio for progression-free survival was 0.979 (95% CI: 0.821 - 1.167) and for overall survival was 0.934 (95% CI: 0.786 - 1.108). Patients receiving CS experienced grade 3 or higher neutropenia, anemia, hyponatremia, and febrile neutropenia more often than those receiving SOX, while those in the the SOX arm experienced grade 3 or higher sensorty neuropathy more often.

The findings suggest that SOX is noninferior to CS for patients with advanced gastric cancer, and therefore, SOX can be used in place of CS.

Vandetanib May Not Be Effective for Advanced Biliary Tract Cancer
Oxaliplatin is as effective as cisplatin for the first-line treatment of patients with advanced gastric cancer.
The authors evaluated the efficacy and safety of S-1 plus oxaliplatin (SOX) as an alternative to cisplatin plus S-1 (CS) in first-line chemotherapy for advanced gastric cancer (AGC). SOX is as effective as CS for AGC with favorable safety profile, therefore SOX can replace CS.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs